Hollencrest Capital Management Supernus Pharmaceuticals, Inc. Transaction History
Hollencrest Capital Management
- $2.41 Billion
- Q4 2024
A detailed history of Hollencrest Capital Management transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Hollencrest Capital Management holds 80 shares of SUPN stock, worth $2,681. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80
Previous 80
-0.0%
Holding current value
$2,681
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.6MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$348 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$206 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$162 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$96.5 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$88.1 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.79B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...